{"news_desk": "SundayBusiness", "print_page": "1", "section_name": "Business Day", "subsection_name": null, "byline": {"contributor": "Rachel Abrams contributed reporting.", "original": "By JULIE CRESWELL and ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "firstname": "Julie", "organization": "", "lastname": "CRESWELL"}, {"rank": 2, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "abstract": "Turing Pharmaceuticals founder and chief executive Martin Shkreli has been vilified for raising price of decades-old drug overnight to $750 a pill from $13.50; he counters that revenue from reinvented drug will fund development of new drugs for debilitating diseases.", "type_of_material": "News", "word_count": "2470", "lead_paragraph": "The chief of Turing Pharmaceuticals, who increased a drug\u2019s price to $750 from $13.50 a pill, has been bashed as the face of corporate greed. But he\u2019s still smiling.", "pub_date": "2015-12-06T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Martin Shkreli, the Bad Boy of Pharmaceuticals, Hits Back", "print_headline": "The Bad Boy of Pharmaceuticals Hits Back"}, "snippet": "The chief of Turing Pharmaceuticals, who increased a drug\u2019s price to $750 from $13.50 a pill, has been bashed as the face of corporate greed. But he\u2019s still smiling.", "multimedia": [{"height": 126, "url": "images/2015/12/06/business/06-SHKRELI/06-SHKRELI-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/12/06/business/06-SHKRELI/06-SHKRELI-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 422, "url": "images/2015/12/06/business/06-SHKRELI/06-SHKRELI-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "422", "xlarge": "images/2015/12/06/business/06-SHKRELI/06-SHKRELI-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/12/06/business/06-SHKRELI/06-SHKRELI-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/12/06/business/06-SHKRELI/06-SHKRELI-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/12/06/business/martin-shkreli-the-bad-boy-of-pharmaceuticals-hits-back.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Shkreli, Martin (1983- )", "name": "persons"}, {"rank": "2", "is_major": "Y", "value": "Turing Pharmaceuticals AG", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Prices (Fares, Fees and Rates)", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Hunter College High School", "name": "organizations"}, {"rank": "6", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}], "blog": [], "_id": "566313a838f0d87104c915eb", "source": "The New York Times"}